Drug discovery approaches to irritable bowel syndrome

  title={Drug discovery approaches to irritable bowel syndrome},
  author={P. Hornby},
  journal={Expert Opinion on Drug Discovery},
  pages={809 - 824}
  • P. Hornby
  • Published 2015
  • Medicine
  • Expert Opinion on Drug Discovery
Introduction: Irritable bowel syndrome (IBS) is defined by symptoms of abdominal pain and altered bowel habits without detectable organic disease. Antidepressants and serotonin receptor modulators are used to treat IBS, but rare serious adverse events highlight the safety hurdle. Newer drugs with secretory and motility effects via local gut mechanisms have been successfully approved for IBS, often by registering first in a related, non-IBS condition to optimize dosing, formulation and… Expand
9 Citations
How can we develop better antispasmodics for irritable bowel syndrome?
  • 1
Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome
  • 1
  • PDF
G protein‐coupled estrogen receptor and estrogen receptor ligands regulate colonic motility and visceral pain
  • M. Zielińska, J. Fichna, +4 authors M. Storr
  • Biology, Medicine
  • Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2017
  • 25
Serotonergic Mechanisms Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance.
  • 30
Enteric Neuronal Regulation of Intestinal Inflammation
  • 44
  • PDF
CTG-19-0299 1..9


    Emerging receptor target in the pharmacotherapy of irritable bowel syndrome with constipation
    • 17
    • Highly Influential
    Current and Emerging Pharmacotherapeutic Options for Irritable Bowel Syndrome
    • 15
    • PDF
    Irritable bowel syndrome: the role of food in pathogenesis and management.
    • 30
    • PDF
    The safety of novel drugs used to treat irritable bowel syndrome
    • 12
    Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome
    • 44
    Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds.
    • M. Callahan
    • Medicine
    • Journal of clinical gastroenterology
    • 2002
    • 58
    • Highly Influential
    Pharmacologic Therapy for the Irritable Bowel Syndrome
    • N. Talley
    • Medicine
    • American Journal of Gastroenterology
    • 2003
    • 61
    Convergence of neuro-endocrine-immune pathways in the pathophysiology of irritable bowel syndrome.
    • 33
    The quest for biomarkers in IBS—where should it lead us?
    • 24